Introduction: Colorectal cancer is the third most common malignant neoplasm in the world, and its development is associated with environmental factors, family history, age, and genetic predisposition. This latter factor has been extensively studied, and numerous genomic alterations associated with the emergence and progression of this type of cancer have been identified. Cancer cell lines are excellent models for in vitro studies that seek to identify altered cellular pathways, mutations in genes critical to/for cancer, and anticancer drug testing, among others. In this sense, the genomic characterization of cancer cell lines by Array Comparative Genomic Hybridization (aCGH) has been used as a resource to evaluate alterations associated with different types of cancer. The HCT-8 cell line, derived from a human colorectal adenocarcinoma, has been used in in vitro studies to evaluate antitumor drugs; however, no genomic characterization has been performed to date. Objectives: Characterize and validate cytogenomic alterations in HCT-8 cell line as a potential model in colorectal cancer. Methods: HCT-8 cells were thawed, cultured in DMEM supplemented with 10% fetal bovine serum, and maintained until reaching 80–90% confluence. Metaphase chromosomes were obtained using Colcemid treatment for cytogenetic analysis. Genomic DNA was extracted and processed using the SurePrint G3 Human Genome CGH+SNP Microarray Kit for aCGH analysis, allowing the detection of copy number alterations (CNAs) across the genome. Results: The analysis revealed that the modal diploid number was 2n = 46, and a total of 125 CNAs were identified, including 19 gains, 9 losses, 2 deletions, 2 amplifications, and 93 regions of loss of heterozygosity, affecting nearly all chromosomes except 21 and 22. The main gains were observed on chromosomes 14, 18, and X, while the most significant losses occurred on chromosomes 3, 7, and 18. A total of 84 genes were found to be altered in the HCT-8 cell line, many of which have been previously described in tumor samples and are directly associated with the carcinogenesis of colorectal carcinomas, including TP53, KRAS, DCC, SMAD4, and PTEN. Additionally, other altered genes in the cell line may serve as potential biomarkers. Conclusion: In conclusion, the cytogenomic characterization of the HCT-8 cell line confirmed that the cell line is a potential model for in vitro studies to understand the carcinogenesis of colorectal adenocarcinoma, as well as for analyzing the effect of drugs, understanding the therapeutic response, and testing compounds with anticancer potential.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
